Insulin detemir for the treatment of obese patients with type 2 diabetes

References

• National Diabetes Information Clearinghouse National Diabetes Statistics 2007 Available from: http://diabetes.niddk.nih.gov/dm/pubs/statistics/#allages Accessed October 6, 2011
   Google Scholar
• Geiss LS Pan L Cadwell B Gregg EW Benjamin SM Engelgau MM Changes in incidence of diabetes in US adults, 1997–2003 Am J Prev Med 2006 30 5 371 377 16627124
   PubMed Web of Science ®Google Scholar
• Bays HE Chapman RH Grandy S The relationship of body mass index to diabetes mellitus, hypertension and dyslipidaemia: comparison of data from two national surveys Int J Clin Pract 2007 61 5 737 747 17493087
   PubMed Web of Science ®Google Scholar
• Wei M Gaskill SP Haffner SM Stern MP Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality. The San Antonio Heart Study Diabetes Care 1998 21 7 1167 1172 9653614
   PubMed Web of Science ®Google Scholar
• Peters AL Patient and treatment perspectives: Revisiting the link between type 2 diabetes, weight gain, and cardiovascular risk Cleve Clin J Med 2009 76 Suppl 5 S20 S27 19952300
   PubMedGoogle Scholar
• Campbell IW Comparing the actions of older and newer therapies on body weight: to what extent should these effects guide the selection of antidiabetic therapy? Int J Clin Pract 2010 64 6 791 801 20518953
   PubMed Web of Science ®Google Scholar
• Russell-Jones D Khan R Insulin-associated weight gain in diabetes – causes, effects and coping strategies Diabetes Obes Metab 2007 9 6 799 812 17924864
   PubMed Web of Science ®Google Scholar
• Pi-Sunyer FX The impact of weight gain on motivation, compliance, and metabolic control in patients with type 2 diabetes mellitus Postgrad Med 2009 121 5 94 107 19820278
   PubMed Web of Science ®Google Scholar
• Wing RR Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial Arch Intern Med 2010 170 17 1566 1575 20876408
   PubMedGoogle Scholar
• Hollander PA Elbein SC Hirsch IB Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study Diabetes Care 1998 21 8 1288 1294 9702435
   PubMed Web of Science ®Google Scholar
• Esposito K Pontillo A Di Palo C Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial JAMA 2003 289 14 1799 1804 12684358
   PubMed Web of Science ®Google Scholar
• Cox KL Puddey IB Morton AR Burke V Beilin LJ McAleer M Exercise and weight control in sedentary overweight men: effects on clinic and ambulatory blood pressure J Hypertens 1996 14 6 779 790 8793702
   PubMed Web of Science ®Google Scholar
• Fernandez-Veledo S Nieto-Vazquez I Vila-Bedmar R Garcia-Guerra L Alonso-Chamorro M Lorenzo M Molecular mechanisms involved in obesity-associated insulin resistance: therapeutical approach Arch Physiol Biochem 2009 115 4 227 239 19673658
   PubMedGoogle Scholar
• Zeyda M Stulnig TM Obesity, inflammation, and insulin resistance – a mini-review Gerontology 2009 55 4 379 386 19365105
   PubMed Web of Science ®Google Scholar
• Yki-Jarvinen H Ryysy L Kauppila M Effect of obesity on the response to insulin therapy in noninsulin-dependent diabetes mellitus J Clin Endocrinol Metab 1997 82 12 4037 4043 9398709
   PubMed Web of Science ®Google Scholar
• Stevens VJ Obarzanek E Cook NR Long-term weight loss and changes in blood pressure: results of the Trials of Hypertension Prevention, phase II Ann Intern Med 2001 134 1 1 11 11187414
   PubMed Web of Science ®Google Scholar
• Shai I Schwarzfuchs D Henkin Y Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet N Engl J Med 2008 359 3 229 241 18635428
   PubMed Web of Science ®Google Scholar
• Pi-Sunyer X Blackburn G Brancati FL Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the Look AHEAD trial Diabetes Care 2007 30 6 1374 1383 17363746
   PubMed Web of Science ®Google Scholar
• Gaede P Pedersen O Multi-targeted and aggressive treatment of patients with type 2 diabetes at high risk: what are we waiting for? Horm Metab Res 2005 37 Suppl 1 76 82 15918115
   PubMed Web of Science ®Google Scholar
• Gaede P Lund-Andersen H Parving HH Pedersen O Effect of a multifactorial intervention on mortality in type 2 diabetes N Engl J Med 2008 358 6 580 591 18256393
   PubMed Web of Science ®Google Scholar
• Carver C Insulin treatment and the problem of weight gain in type 2 diabetes Diabetes Educ 2006 32 6 910 917 17102158
   PubMed Web of Science ®Google Scholar
• Rosenstock J Davies M Home PD Larsen J Koenen C Schernthaner G A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes Diabetologia 2008 51 3 408 416 18204830
   PubMed Web of Science ®Google Scholar
• Swinnen SG Dain MP Aronson R A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugs Diabetes Care 2010 33 6 1176 1178 20200301
   PubMed Web of Science ®Google Scholar
• Valentine WJ Palmer AJ Erny-Albrecht KM Cost-effectiveness of basal insulin from a US health system perspective: comparative analyses of detemir, glargine, and NPH Adv Ther 2006 23 2 191 207 16751153
   PubMed Web of Science ®Google Scholar
• DeFronzo RA Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus Diabetes 2009 58 4 773 795 19336687
   PubMed Web of Science ®Google Scholar
• Meece J Dispelling myths and removing barriers about insulin in type 2 diabetes Diabetes Educ 2006 32 1 Suppl 9S 18S 16439485
   PubMed Web of Science ®Google Scholar
• Eliasson B Eeg-Olofsson K Cederholm J Nilsson PM Gudbjornsdottir S Antihyperglycaemic treatment of type 2 diabetes: results from a national diabetes register Diabetes Metab 2007 33 4 269 276 17499541
   PubMed Web of Science ®Google Scholar
• Laville M Andreelli F Mechanisms for weight gain during blood glucose normalization Diabetes Metab 2000 26 Suppl 3 42 45 10945152
   PubMed Web of Science ®Google Scholar
• Groop L Widen E Franssila-Kallunki A Different effects of insulin and oral antidiabetic agents on glucose and energy metabolism in type 2 (non-insulin-dependent) diabetes mellitus Diabetologia 1989 32 8 599 605 2506091
   PubMed Web of Science ®Google Scholar
• Hartman I Insulin analogs: impact on treatment success, satisfaction, quality of life, and adherence Clin Med Res 2008 6 2 54 67 18801953
   PubMedGoogle Scholar
• Russell-Jones D Simpson R Hylleberg B Draeger E Bolinder J Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen Clin Ther 2004 26 5 724 736 15220016
   PubMed Web of Science ®Google Scholar
• Home P Bartley P Russell-Jones D Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial Diabetes Care 2004 27 5 1081 1087 15111525
   PubMed Web of Science ®Google Scholar
• Hermansen K Davies M Derezinski T Ravn GM Clauson P Home P A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes Diabetes Care 2006 29 6 1269 1274 16732007
   PubMed Web of Science ®Google Scholar
• Skyler JS Bergenstal R Bonow RO Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association Diabetes Care 2009 32 1 187 192 19092168
   PubMed Web of Science ®Google Scholar
• Chapman TM Perry CM Insulin detemir: a review of its use in the management of type 1 and 2 diabetes mellitus Drugs 2004 64 22 2577 2595 15516157
   PubMed Web of Science ®Google Scholar
• Philips JC Scheen A Insulin detemir in the treatment of type 1 and type 2 diabetes Vasc Health Risk Manag 2006 2 3 277 283 17326333
   PubMedGoogle Scholar
• Levemir® (insulin detemir [rDNA origin] injection) Prescribing information Princeton, NJ Novo Nordisk Inc 11 2010
   Google Scholar
• Havelund S Plum A Ribel U The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin Pharm Res 2004 21 8 1498 1504 15359587
   PubMed Web of Science ®Google Scholar
• King AB Once-daily insulin detemir is comparable to once-daily insulin glargine in providing glycaemic control over 24 h in patients with type 2 diabetes: a double-blind, randomized, crossover study Diabetes Obes Metab 2009 11 1 69 71 19120433
   PubMed Web of Science ®Google Scholar
• Bott S Tusek C Jacobsen LV Insulin detemir under steady-state conditions: no accumulation and constant metabolic effect over time with twice daily administration in subjects with type 1 diabetes Diabet Med 2006 23 522 528 16681561
   PubMed Web of Science ®Google Scholar
• Plank J Bodenlenz M Sinner F A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir Diabetes Care 2005 28 5 1107 1112 15855574
   PubMed Web of Science ®Google Scholar
• Klein O Lynge J Endahl L Damholt B Nosek L Heise T Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes Diabetes Obes Metab 2007 9 3 290 299 17391154
   PubMed Web of Science ®Google Scholar
• Heise T Pieber TR Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies Diabetes Obes Metab 2007 9 5 648 659 17645556
   PubMed Web of Science ®Google Scholar
• Heise T Nosek L Ronn BB Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes Diabetes 2004 53 6 1614 1620 15161770
   PubMed Web of Science ®Google Scholar
• Sreenan S Virkamaki A Zhang K Hansen JB Switching from NPH insulin to once-daily insulin detemir in basal-bolus-treated patients with diabetes mellitus: data from the European cohort of the PREDICTIVE study Int J Clin Pract 2008 62 12 1971 1980 19166444
   PubMed Web of Science ®Google Scholar
• Fajardo Montanana C Hernandez Herrero C Rivas Fernandez M Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight type 2 diabetes patients – the PREDICTIVE™ BMI clinical trial Diabet Med 2008 25 8 916 923 18959604
   PubMed Web of Science ®Google Scholar
• Raslova K Tamer SC Clauson P Karl D Insulin detemir results in less weight gain than NPH insulin when used in basal-bolus therapy for type 2 diabetes mellitus, and this advantage increases with baseline body mass index Clin Drug Invest 2007 27 4 279 285
   PubMed Web of Science ®Google Scholar
• Philis-Tsimikas A Charpentier G Clauson P Martinez Ravn G Roberts VL Thorsteinsson B Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes Clin Ther 2006 28 10 1569 1581 17157113
   PubMed Web of Science ®Google Scholar
• Hollander P Cooper J Bregnhoj J Pedersen CB A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes Clin Ther 2008 30 11 1976 1987 19108786
   PubMed Web of Science ®Google Scholar
• Raskin P Gylvin T Weng W Chaykin L Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes Diabetes Metab Res Rev 2009 25 6 542 548 19565569
   PubMed Web of Science ®Google Scholar
• Fakhoury W Lockhart I Kotchie RW Aagren M Lereun C Indirect comparison of once daily insulin detemir and glargine in reducing weight gain and hypoglycaemic episodes when administered in addition to conventional oral anti-diabetic therapy in patients with type-2 diabetes Pharmacology 2008 82 2 156 163 18679040
   PubMed Web of Science ®Google Scholar
• Philis-Tsimikas A Zhang Q Walker C Glycemic control with insulin glargine as part of an ethnically diverse, community-based diabetes management program Am J Ther 2006 13 6 466 472 17122525
   PubMedGoogle Scholar
• Blonde L Merilainen M Karwe V Raskin P Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets – the TITRATE study Diabetes Obes Metab 2009 11 6 623 631 19515182
   PubMed Web of Science ®Google Scholar
• Garber AJ Clauson P Pedersen CB Kolendorf K Lower risk of hypoglycemia with insulin detemir than with neutral protamine hagedorn insulin in older persons with type 2 diabetes: a pooled analysis of phase III trials J Am Geriatr Soc 2007 55 11 1735 1740 17979896
   PubMed Web of Science ®Google Scholar
• Home PD Fritsche A Schinzel S Massi-Benedetti M Meta-analysis of individual patient data to assess the risk of hypoglycaemia in people with type 2 diabetes using NPH insulin or insulin glargine Diabetes Obes Metab 2010 12 9 772 779 20649629
   PubMed Web of Science ®Google Scholar
• Hermansen K Davies M Does insulin detemir have a role in reducing risk of insulin-associated weight gain? Diabetes Obes Metab 2007 9 3 209 217 17391147
   PubMed Web of Science ®Google Scholar
• Singh SR Ahmad F Lal A Yu C Bai Z Bennett H Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis CMAJ 2009 180 4 385 397 19221352
   PubMed Web of Science ®Google Scholar
• Davies MJ Derezinski T Pedersen CB Clauson P Reduced weight gain with insulin detemir compared to NPH insulin is not explained by a reduction in hypoglycemia Diabetes Technol Ther 2008 10 4 273 277 18715200
   PubMed Web of Science ®Google Scholar
• Tschritter O Schafer SA Klett J Insulin detemir causes increased symptom awareness during hypoglycaemia compared to human insulin Diabetes Obes Metab 2009 11 11 1017 1026 19650876
   PubMed Web of Science ®Google Scholar
• Hordern SV Wright JE Umpleby AM Shojaee-Moradie F Amiss J Russell-Jones DL Comparison of the effects on glucose and lipid metabolism of equipotent doses of insulin detemir and NPH insulin with a 16-h euglycaemic clamp Diabetologia 2005 48 420 426 15729576
   PubMed Web of Science ®Google Scholar
• Hallschmid M Benedict C Schultes B Fehm HL Born J Kern W Intranasal insulin reduces body fat in men but not in women Diabetes 2004 53 11 3024 3029 15504987
   PubMed Web of Science ®Google Scholar
• Hallschmid M Jauch-Chara K Korn O Euglycemic infusion of insulin detemir compared to human insulin appears to increase direct current brain potential response and reduces food intake while inducing similar systemic effects Diabetes 2010 59 4 1101 1107 20068139
   PubMed Web of Science ®Google Scholar
• Banks WA Morley JE Lynch JL Lynch KM Mooradian AD Insulin detemir is not transported across the blood-brain barrier Peptides 2010 31 12 2284 2288 20868713
   PubMed Web of Science ®Google Scholar
• Jessen L Clegg DJ Bouman SD Evaluation of the lack of anorectic effect of intracerebroventricular insulin in rats Am J Physiol Regul Integr Comp Physiol 2010 298 1 R43 R50 19864335
   PubMed Web of Science ®Google Scholar
• Fledelius C Damgaard J Vinterby A Ribel U Petersen JS Sturis J Insulin detemir reduces gain in bodyweight and fat mass in ZDF rats when compared with both NPH and insulin glargine Diabetologia 2008 51 Suppl 1 S392 (abstr 975)
   Google Scholar
• Fledelius C Olsen GS Jensen AB The weight sparing effect of insulin detemir is associated with increased adiponectin levels and decreased adiposity in the diabetic ZDF rat Diabetologia 2009 52 Suppl 1 S285 (abstr 727)
   Google Scholar
• Haluzik M Parizkova J Haluzik MM Adiponectin and its role in the obesity-induced insulin resistance and related complications Physiol Res 2004 53 2 123 129 15046547
   PubMed Web of Science ®Google Scholar
• Boden G Laakso M Lipids and glucose in type 2 diabetes: what is the cause and effect? Diabetes Care 2004 27 9 2253 2259 15333497
   PubMed Web of Science ®Google Scholar
• Jung CH Rhee EJ Choi JH The relationship of adiponectin/leptin ratio with homeostasis model assessment insulin resistance index and metabolic syndrome in apparently healthy korean male adults Korean Diabetes J 2010 34 4 237 243 20835341
   PubMedGoogle Scholar
• Bohm A Staiger H Hennige AM Haas C Machicao F Haring HU Effect of insulin detemir, compared to human insulin, on 3T3-L1 adipogenesis Regul Pept 2008 151 1–3 160 163 18571747
   PubMedGoogle Scholar
• Tibaldi J Actions of insulin beyond glycemic control: a perspective on insulin detemir Adv Ther 2007 24 4 868 882 17901036
   PubMed Web of Science ®Google Scholar